Reports have said that Beijing is speaking out against the US court that recently ordered two Chinese manufacturers of Vitamin C to pay $162 million in damages for price-fixing. The US court is now accused of infringing on Beijing’s sovereignty. A spokesman for China’s Ministry of Commerce spoke out against the US court at a press conference, arguing that the ruling was “unfair and improper” and that the accused companies were simply complying with the Chinese government’s requirements. Last week a federal court in New York ordered that North China Pharmaceutical Group Corp and one of its affiliates to pay the fine after the defendants argued that the “price-fixing cartel” found to have existed by the jury was the result of Chinese government decisions. The fines were trebled by the judge.
Featured News
Federal Antitrust Suit Targeting Aircraft Engine Sales Practices Is Settled
Dec 31, 2025 by
CPI
CFTC Withdraws Guidance on ‘Actual Delivery’ in Crypto Transactions, Leaving Regulatory Void
Dec 31, 2025 by
CPI
Coalition of State AGs Push Back Against FCC Proposal Seeking to Preempt State AI Laws
Dec 31, 2025 by
CPI
Apple Seeks to Overturn £1.5 Billion UK App Store Antitrust Ruling
Dec 31, 2025 by
CPI
Age-Restriction Laws Are Proliferating; So Too Are the Difficult Tradeoffs Policymakers Face
Dec 23, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi